Clinical Trial

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

Study acronym: ASOTARI
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2024 (before its estimated October 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.
Trial Details
NCT Number NCT06451172
Lead Sponsor Eye & ENT Hospital of Fudan University
Collaborators: Soochow University
Conditions Bacterial Keratitis, Antibiotic-resistant Bacteria, Infections, Bacterial, Corneal Diseases, Eye Diseases, Vision Disorders, Sensation Disorders, Blindness +2 more
Enrollment 20 participants
Start Date 2023-10-11
Primary Completion 2024-10-01 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-11